<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.1d3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">70700</article-id><article-id pub-id-type="doi">10.7554/eLife.70700</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Medicine</subject></subj-group></article-categories><title-group><article-title>Selective androgen receptor degrader (SARD) to overcome antiandrogen resistance in castration-resistant prostate cancer</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-240314"><name><surname>Wu</surname><given-names>Meng</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-240315"><name><surname>Zhang</surname><given-names>Rongyu</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-240316"><name><surname>Zhang</surname><given-names>Zixiong</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-240320"><name><surname>Zhang</surname><given-names>Ning</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-240317"><name><surname>Li</surname><given-names>Chenfan</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-240318"><name><surname>Xie</surname><given-names>Yongli</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-270968"><name><surname>Xia</surname><given-names>Haoran</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-240319"><name><surname>Huang</surname><given-names>Fangjiao</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-240321"><name><surname>Zhang</surname><given-names>Ruoying</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-288342"><name><surname>Liu</surname><given-names>Ming</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-240322"><name><surname>Li</surname><given-names>Xiaoyu</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-225411"><name><surname>Cen</surname><given-names>Shan</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-239962"><name><surname>Zhou</surname><given-names>Jinming</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-1610-5061</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="corresp" rid="cor2">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><institution content-type="dept">Institute of Medicinal Biotechnology</institution>, <institution>Chinese Academy of Medical Sciences &amp; Peking Union Medical College</institution>, <addr-line><named-content content-type="city">Beijing</named-content></addr-line>, <country>China</country></aff><aff id="aff2"><institution content-type="dept">Department of Chemistry</institution>, <institution>Zhejiang Normal University</institution>, <addr-line><named-content content-type="city">Jinhua</named-content></addr-line>, <country>China</country></aff><aff id="aff3"><institution content-type="dept">Department of Urology</institution>, <institution>Beijing Hospital</institution>, <addr-line><named-content content-type="city">Beijing</named-content></addr-line>, <country>China</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-238838"><name><surname>El-Deiry</surname><given-names>Wafik S</given-names></name><role>Reviewing editor</role><aff><institution>Brown University</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>shancen@imb.pumc.edu.cn</email> (SC);</corresp><corresp id="cor2"><label>*</label>For correspondence: <email>zhoujinming@zjnu.edu.cn</email> (JZ);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>19</day><month>01</month><year>2023</year></pub-date><volume>12</volume><elocation-id>e70700</elocation-id><history><date date-type="received"><day>26</day><month>05</month><year>2021</year></date><date date-type="accepted"><day>18</day><month>01</month><year>2023</year></date></history><permissions><copyright-statement>Â© 2023, Wu et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Wu et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-70700-v1.pdf"/><abstract><p>In patients with castration-resistant prostate cancer (CRPC), clinical resistances such as androgen receptor (AR) mutation, AR overexpression, and AR splice variants (ARVs) limit the effectiveness of second-generation antiandrogens (SGAs). Several strategies have been implemented to develop novel antiandrogens to circumvent the occurring resistance. Here, we found and identified a bifunctional small molecule Z15, which is both an effective AR antagonist and a selective AR degrader. Z15 could directly interact with the ligand-binding domain (LBD) and activation function-1 region of AR, and promote AR degradation through the proteasome pathway. <italic>In vitro</italic> and <italic>in vivo</italic> studies showed that Z15 efficiently suppressed AR, AR mutants and ARVs transcription activity, downregulated mRNA and protein levels of AR downstream target genes, thereby overcoming AR LBD mutations, AR amplification, and ARVs-induced SGAs resistance in CRPC. In conclusion, our data illustrate the synergistic importance of AR antagonism and degradation in advanced prostate cancer treatment.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>22077115,81672559,81311120299</award-id><principal-award-recipient><name><surname>Zhou</surname><given-names>Jinming</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>82104231</award-id><principal-award-recipient><name><surname>Wu</surname><given-names>Meng</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002858</institution-id><institution>China Postdoctoral Science Foundation</institution></institution-wrap></funding-source><award-id>2021M700504</award-id><principal-award-recipient><name><surname>Wu</surname><given-names>Meng</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: All animal experiments have been approved by the Ethics Committee of Nanjing Lambda Pharmaceutical Co.,Ltd (Reference number: IACUC-20210902).</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>Data Availability: All data generated or analysed during this study are included in the manuscript and supporting source files. The RNA sequence data could be found in the following link: https://bigd.big.ac.cn/gsa-human/browse/HRA000921. The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD035721. PRIDE - Proteomics Identification Database (ebi.ac.uk).</p><p>The following datasets were generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><collab>Zhou J</collab><collab>et al</collab></person-group><year iso-8601-date="2023">2023</year><source>Selective androgen receptor degrader (SARD) to overcome antiandrogen resistance in castration-resistant prostate cancer</source><ext-link ext-link-type="uri" xlink:href="URL https://www.ebi.ac.uk/pride/archive/projects/ PXD035721">URL https://www.ebi.ac.uk/pride/archive/projects/ PXD035721</ext-link><comment>PRIDE, PXD035721</comment></element-citation></p></sec><supplementary-material><ext-link xlink:href="elife-70700-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>